Promoted Content
Promoted Content

Find Rheumatology Clinical Drug Pipeline Developments & Deals


All Data

Filters Filter refresh
Study Phase filter
    Country filter
      News Type filter
        Company filter
          Product Type filter

            Product Type Full Screen

            Development Status Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Dotinurad

            Therapeutic Area: Rheumatology Product Name: Undisclosed

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Eisai

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement February 25, 2020


            Under this agreement, Eisai will proceed with the development of dotinurad in China.